These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9259085)

  • 1. Bladder cancer: natural history, tumor markers, and early detection strategies.
    Foresman WH; Messing EM
    Semin Surg Oncol; 1997; 13(5):299-306. PubMed ID: 9259085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle regulators as prognostic factors for bladder cancer.
    Cordon-Cardo C
    Eur Urol; 1998; 33 Suppl 4():11-2. PubMed ID: 9615199
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prognostic factors in urothelial carcinoma].
    Vögeli TA; Ackermann R
    Urologe A; 2001 Nov; 40(6):442-6. PubMed ID: 11760346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting disease outcome of non-invasive transitional cell carcinoma of the urinary bladder using an artificial neural network model: results of patient follow-up for 15 years or longer.
    Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Sasaki M; Takeuchi H; Okabe T
    Int J Urol; 2003 Mar; 10(3):149-52. PubMed ID: 12622711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superficial bladder cancer: part 1. Update on etiology, classification and natural history.
    Josephson DY; Pasin E; Stein JP
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1723-34. PubMed ID: 17181486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
    Soloway MS; Sofer M; Vaidya A
    J Urol; 2002 Apr; 167(4):1573-83. PubMed ID: 11912367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art.
    Williamson SR; Montironi R; Lopez-Beltran A; MacLennan GT; Davidson DD; Cheng L
    Crit Rev Oncol Hematol; 2010 Nov; 76(2):112-26. PubMed ID: 20097572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current developments in the diagnostics and therapy of bladder carcinoma].
    Kamradt J; Ohlmann CH; Stöckle M
    Urologe A; 2011 Sep; 50 Suppl 1():179-83. PubMed ID: 21863408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion.
    Brimo F; Wu C; Zeizafoun N; Tanguay S; Aprikian A; Mansure JJ; Kassouf W
    Hum Pathol; 2013 Jan; 44(1):95-102. PubMed ID: 22939956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology of transitional cell carcinoma of the bladder and its clinical implications.
    Lapham RL; Ro JY; Staerkel GA; Ayala AG
    Semin Surg Oncol; 1997; 13(5):307-18. PubMed ID: 9259086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [From marker expression to individual therapy of patients with bladder cancer].
    Vom Dorp F; Börgermann C; Jäger T; Becker M; Schmid KW; Rübben H
    Urologe A; 2008 Sep; 47(9):1167-70. PubMed ID: 18712513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ.
    Althausen AF; Prout GR; Daly JJ
    J Urol; 1976 Nov; 116(5):575-80. PubMed ID: 978809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
    Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
    Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in the pathophysiology of bladder cancer.
    Rozanski TA; Grossman HB
    AJR Am J Roentgenol; 1994 Oct; 163(4):789-92. PubMed ID: 8092012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superficial bladder cancer.
    Itoku KA; Stein BS
    Hematol Oncol Clin North Am; 1992 Feb; 6(1):99-116. PubMed ID: 1556055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma.
    Pagano F; Garbeglio A; Milani C; Bassi P; Pegoraro V
    Eur Urol; 1987; 13(3):145-9. PubMed ID: 3609087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
    Bach T; Bastian PJ; Blana A; Kaminsky A; Keller S; Knoll T; Lang C; Promnitz S; Ubrig B; Keller T; Qvick B; Burger M;
    World J Urol; 2017 May; 35(5):737-744. PubMed ID: 27578233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of markers in defining urothelial premalignant and malignant conditions.
    Grossman HB; Schmitz-Dräger B; Fradet Y; Tribukait B
    Scand J Urol Nephrol Suppl; 2000; (205):94-104. PubMed ID: 11144908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.